Boehringer, Carnot, Bayer, and AstraZeneca Announce MXN 12 Billion Investment in Mexico

Four leading pharmaceutical companies—Boehringer Ingelheim, Laboratorios Carnot, Bayer, and AstraZeneca—have announced a joint investment of over MXN 12 billion to expand their operations in Mexico. The projects include new manufacturing plants, advanced production centers, and the expansion of digital services. These investments reaffirm Mexico's role as a strategic hub for pharmaceutical production, research, and global exports.

Boehringer, Carnot, and Bayer Expand Global Manufacturing Capacity

Boehringer Ingelheim will invest MXN 3 billion to transform its Xochimilco facility into the company’s largest tablet production plant worldwide, with the capacity to produce 5 billion units per year and export to over 40 countries. The project is expected to generate 1,800 direct jobs and around 15,000 indirect jobs, reinforcing Mexico’s skilled workforce as a key driver in the industry.

Mexican company Laboratorios Carnot will allocate MXN 3.5 billion to build a new plant in Hidalgo, specializing in pharmaceutical and biotechnological technology. The facility will generate 600 highly specialized direct jobs and at least 5,000 indirect ones, focusing on high-value manufacturing with export potential to over 30 countries.

Meanwhile, Bayer will invest MXN 3 billion over the next five years, primarily to expand its Orizaba site for the production of active pharmaceutical ingredients (APIs). The company will also introduce new production lines at its Lerma facility and expand its Tlaxcala plant. Additionally, Bayer will integrate digital sensors for agricultural use and triple its investment in clinical trials in Mexico, leveraging recent regulatory improvements.

AstraZeneca Focuses on Innovation, Clinical Research, and Manufacturing

AstraZeneca announced a MXN 2 billion investment targeting three core areas: clinical research in partnership with national universities and institutes; the expansion of its digital and technology service center; and an increase in production capacity at its facility in the State of Mexico. Overall, the investment will create more than 600 direct jobs and 6,500 indirect jobs.

These investments not only strengthen the domestic and international supply of essential medicines, but also support health sovereignty, foster pharmaceutical innovation, and position Mexico as a competitive hub for the life sciences industry in Latin America.